Allergan has joined with the genome editing company Editas Medicine to develop and commercialize EDIT-101 CRISPR genome editing medicine for the treatment of Leber congenital amaurosis type 10, according to a press release.
The companies will co-develop and equally share profits and losses from the experimental medicine in the United States.
“CRISPR-based medicines have the potential to be game-changers for patients with both genetically defined and genetically treatable diseases of the eye,” David Nicholson, PhD, Allergan chief research and development officer, said in the release.
Uncategorized